209 related articles for article (PubMed ID: 21177320)
1. Magnetic resonance imaging as surrogate for clinical endpoints in multiple sclerosis: data on novel oral drugs.
Sormani MP; Bonzano L; Roccatagliata L; De Stefano N
Mult Scler; 2011 May; 17(5):630-3. PubMed ID: 21177320
[TBL] [Abstract][Full Text] [Related]
2. Magnetic resonance active lesions as individual-level surrogate for relapses in multiple sclerosis.
Sormani MP; Stubinski B; Cornelisse P; Rocak S; Li D; De Stefano N
Mult Scler; 2011 May; 17(5):541-9. PubMed ID: 21148262
[TBL] [Abstract][Full Text] [Related]
3. Emerging disease-modifying oral therapies for multiple sclerosis.
Losy J; Kalinowska-Łyszczarz A
J Neuroimmunol; 2011 Feb; 231(1-2):15-22. PubMed ID: 20947176
[TBL] [Abstract][Full Text] [Related]
4. A placebo-controlled trial of oral fingolimod in relapsing multiple sclerosis.
Kappos L; Radue EW; O'Connor P; Polman C; Hohlfeld R; Calabresi P; Selmaj K; Agoropoulou C; Leyk M; Zhang-Auberson L; Burtin P;
N Engl J Med; 2010 Feb; 362(5):387-401. PubMed ID: 20089952
[TBL] [Abstract][Full Text] [Related]
5. [Development of oral therapies for multiple sclerosis--fingolimod, cladribine and other drugs].
Hecht B
Med Monatsschr Pharm; 2010 Apr; 33(4):120-30; quiz 131-2. PubMed ID: 20429402
[TBL] [Abstract][Full Text] [Related]
6. The use of MRI as an outcome measure in clinical trials.
Li DK; Li MJ; Traboulsee A; Zhao G; Riddehough A; Paty D
Adv Neurol; 2006; 98():203-26. PubMed ID: 16400836
[TBL] [Abstract][Full Text] [Related]
7. [Assessment of the clinical and MRI results of the FREEDOMS and TRANSFORMS phase III. clinical trials].
Jakab G
Ideggyogy Sz; 2012 May; 65(5-6):207-8. PubMed ID: 22724290
[No Abstract] [Full Text] [Related]
8. Magnetic resonance imaging metrics and their correlation with clinical outcomes in multiple sclerosis: a review of the literature and future perspectives.
Bar-Zohar D; Agosta F; Goldstaub D; Filippi M
Mult Scler; 2008 Jul; 14(6):719-27. PubMed ID: 18424478
[TBL] [Abstract][Full Text] [Related]
9. Oral fingolimod (gilenya) for multiple sclerosis.
Med Lett Drugs Ther; 2010 Dec; 52(1353-1354):98-9. PubMed ID: 21344782
[No Abstract] [Full Text] [Related]
10. Delayed fingolimod-associated asystole.
Espinosa PS; Berger JR
Mult Scler; 2011 Nov; 17(11):1387-9. PubMed ID: 21652609
[TBL] [Abstract][Full Text] [Related]
11. Oral fingolimod (FTY720) in multiple sclerosis: two-year results of a phase II extension study.
O'Connor P; Comi G; Montalban X; Antel J; Radue EW; de Vera A; Pohlmann H; Kappos L;
Neurology; 2009 Jan; 72(1):73-9. PubMed ID: 19122034
[TBL] [Abstract][Full Text] [Related]
12. Emerging oral agents for multiple sclerosis.
Fox EJ
Am J Manag Care; 2010 Sep; 16(8 Suppl):S219-26. PubMed ID: 20873946
[TBL] [Abstract][Full Text] [Related]
13. New oral drugs for multiple sclerosis.
Gasperini C; Ruggieri S
Neurol Sci; 2009 Oct; 30 Suppl 2():S179-83. PubMed ID: 19882371
[TBL] [Abstract][Full Text] [Related]
14. Phase II study of oral fingolimod (FTY720) in multiple sclerosis: 3-year results.
Comi G; O'Connor P; Montalban X; Antel J; Radue EW; Karlsson G; Pohlmann H; Aradhye S; Kappos L;
Mult Scler; 2010 Feb; 16(2):197-207. PubMed ID: 20028707
[TBL] [Abstract][Full Text] [Related]
15. Oral fingolimod or intramuscular interferon for relapsing multiple sclerosis.
Cohen JA; Barkhof F; Comi G; Hartung HP; Khatri BO; Montalban X; Pelletier J; Capra R; Gallo P; Izquierdo G; Tiel-Wilck K; de Vera A; Jin J; Stites T; Wu S; Aradhye S; Kappos L;
N Engl J Med; 2010 Feb; 362(5):402-15. PubMed ID: 20089954
[TBL] [Abstract][Full Text] [Related]
16. Advanced magnetic resonance imaging metrics: implications for multiple sclerosis clinical trials.
Zivadinov R
Methods Find Exp Clin Pharmacol; 2009; 31(1):29-40. PubMed ID: 19357796
[TBL] [Abstract][Full Text] [Related]
17. Emerging tumefactive multiple sclerosis after switching therapy from natalizumab to fingolimod.
Jander S; Turowski B; Kieseier BC; Hartung HP
Mult Scler; 2012 Nov; 18(11):1650-2. PubMed ID: 23100527
[TBL] [Abstract][Full Text] [Related]
18. [Progress of therapy in patients with multiple sclerosis].
Kümpfel T; Havla J; Hohlfeld R
MMW Fortschr Med; 2010 Mar; 152(9):42-4. PubMed ID: 20384096
[No Abstract] [Full Text] [Related]
19. MRI as an outcome in multiple sclerosis clinical trials.
Daumer M; Neuhaus A; Morrissey S; Hintzen R; Ebers GC
Neurology; 2009 Feb; 72(8):705-11. PubMed ID: 19073945
[TBL] [Abstract][Full Text] [Related]
20. Current disease-modifying treatment of multiple sclerosis.
Derwenskus J
Mt Sinai J Med; 2011; 78(2):161-75. PubMed ID: 21425262
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]